C. difficile Toxoid Vaccine (Clostridium Difficile Infection Vaccine) — Pipeline & Regulatory Status

Program Status: Inactive / Discontinued

Reason: Registry status: TERMINATED

Stage at discontinuation: phase_3

Development Phase Discontinued / Inactive Primary Status

Platform Technology Toxoid Biologic Architecture

Target Indication Clostridium Difficile Infection Pathogen / Antigen

Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority	Status & Details
US FDA	Not Filed / Pre-submission
EMA (Europe)	Not Filed / Pre-submission
Health Canada	Not Filed / Pre-submission
TGA (Australia)	Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture: Toxoid
Lead Developer: Sanofi Pasteur, a Sanofi Company
Next Expected Milestone: Primary completion (most advanced trial): 2018-06-12 (registry estimate)
Analyst & Development Notes: Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation: ClinicalTrials.gov NCT01887912 →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT01887912 Discontinued / Inactive

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Status: Active / Ongoing • Expected Readout: 2018-06-12

Milestone Overview

Stage Verification

Discontinued / Inactive confirmed as of 2026-07-10.
Target Milestone

Primary completion (most advanced trial): 2018-06-12 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.